Midazolam as a potential CYP3A phenotyping probe for cabazitaxel metabolism.

Recruiting

• Conditions: prostate cancer - bone metastases; 10027476

• Registration Number: NL-OMON37899
• Lead Sponsor: Meander Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

Metastasized hormone refractory prostate cancer.
Progression of disease during or after treatment with docetaxel.

Exclusion Criteria

Severe dyspnea
Myasthenia Gravis
Sleep apnea syndrome.
Severe hepatic dysfunction
Age 80 years and older

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics of midazolam and cabazitaxel. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Does not apply</p><br>